<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531777</url>
  </required_header>
  <id_info>
    <org_study_id>APTN-II-CRC</org_study_id>
    <nct_id>NCT01531777</nct_id>
  </id_info>
  <brief_title>Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer</brief_title>
  <official_title>A Random, Open, Dose Finding and Pharmacokinetics/Pharmacodynamics(PK/PD) Phase II Study of Apatinib Tablets in the Treatment of Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE:&#xD;
&#xD;
      Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor&#xD;
      receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. The&#xD;
      investigators' phase I study has shown that the drug's toxicity is manageable.&#xD;
&#xD;
      PURPOSE:&#xD;
&#xD;
        1. Studying how well Apatinib works in treating patients.&#xD;
&#xD;
        2. Finding the efficacy and safety of 500 mg or 750mg Apatinib.&#xD;
&#xD;
        3. Pharmacokinetics/Pharmacodynamics(PK/PD).&#xD;
&#xD;
        4. Exploring new outcome measures of antiangiogenic drugs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR (Objective Response Rate)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DCR (Disease Control Rate)</measure>
    <time_frame>12 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (Overall Survival)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL (Quality of Life)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500mg,p.o.,qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apatinib 750mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>750mg,p.o.,qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.</description>
    <arm_group_label>Apatinib 500mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apatinib</intervention_name>
    <description>750 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.</description>
    <arm_group_label>Apatinib 750mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 and ≤ 70 years of age&#xD;
&#xD;
          -  Histological confirmed advanced or metastatic colorectal Cancer，at least one&#xD;
             measurable lesion, larger than 10 mm in diameter by spiral CT scan(scanning layer ≤ 5&#xD;
             mm )&#xD;
&#xD;
          -  Have failed for ≥ 2 lines of chemotherapy&#xD;
&#xD;
          -  Life expectancy of more than 3 months&#xD;
&#xD;
          -  ECOG performance scale ≤ 1&#xD;
&#xD;
          -  Duration from the last therapy is more than 6 weeks for nitroso or mitomycin More than&#xD;
             4 weeks for operation, radiotherapy or cytotoxic agents&#xD;
&#xD;
          -  Adequate hepatic, renal, heart, and hematologic functions (platelets &gt; 80 × 10E+9/L,&#xD;
             neutrophil &gt; 1.5 × 10E+9/L, serum creatinine ≤ 1×upper limit of normal(ULN), bilirubin&#xD;
             &lt; 1.25 ULN, and serum transaminase ≤ 2.5× ULN)&#xD;
&#xD;
          -  Child bearing potential, a negative urine or serum pregnancy test result before&#xD;
             initiating apatinib, must agree and commit to the use of a reliable method of birth&#xD;
             control for the duration of the study and for 8 weeks after the last dose of test&#xD;
             article. Male: All subjects who are not surgically sterile or postmenopausal must&#xD;
             agree and commit to the use of a reliable method of birth control for the duration of&#xD;
             the study and for 8 weeks after the last dose of test article.&#xD;
&#xD;
          -  Signed and dated informed consent. Willingness and ability to comply with scheduled&#xD;
             visits, treatment plans, laboratory tests, and other study procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma&#xD;
             in-situ of uterine cervix&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Preexisting uncontrolled hypertension defined as more than 140/90 mmHg despite using&#xD;
             single medical therapy, more than class I (NCI CTCAE 3.0 ) myocardial ischemia,&#xD;
             arrhythmia(including QTcF:male ≥ 450 ms, female ≥ 470 ms), or cardiac insufficiency&#xD;
             myocardial ischemia, arrhythmia, or cardiac insufficiency&#xD;
&#xD;
          -  Before or at the same time any, second malignancies except cured basal cell carcinoma&#xD;
             of skin and carcinoma in-situ of uterine cervix&#xD;
&#xD;
          -  Any factors that influence the usage of oral administration Evidence of CNS metastasis&#xD;
&#xD;
          -  URT: urine protein ≥ (++)and &gt; 1.0 g of 24 h&#xD;
&#xD;
          -  PT, APTT, TT, Fbg abnormal, having hemorrhagic tendency (eg. active peptic ulcer&#xD;
             disease) or receiving the therapy of thrombolysis or anticoagulation&#xD;
&#xD;
          -  Abuse of drugs&#xD;
&#xD;
          -  Certain possibility of gastric or intestine hemorrhage&#xD;
&#xD;
          -  Less than 4 weeks from the last clinical trial&#xD;
&#xD;
          -  Viral hepatitis type B or type C&#xD;
&#xD;
          -  Prior VEGFR inhibitor treatment&#xD;
&#xD;
          -  Evidence of significant medical illness that in the investigator's judgment will&#xD;
             substantially increase the risk associated with the subject's participation in and&#xD;
             completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University cancer hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>February 7, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2012</study_first_posted>
  <last_update_submitted>April 2, 2015</last_update_submitted>
  <last_update_submitted_qc>April 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

